A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Ki vehet részt

• Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
• Must have histologically or cytologically confirmed diagnosis of one of the following:; Adenocarcinoma of the pancreas; Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer; HER2-positive breast cancer; Triple negative breast cancer (TNBC); Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma); Gastric cancer (adenocarcinoma); Colorectal cancer (CRC); Esophageal cancer (squamous cell carcinoma or adenocarcinoma); Cholangiocarcinoma; Other non- central nervous system (CNS) solid tumors, which have demonstrated FAP uptake via positron emission tomography (PET),
• Must have received prior treatments as indicated below:; Phase 1a; Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease; HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor; HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available); TNBC: Participants must have received at least 1 prior line of therapy for metastatic disease, and must have received an ADC unless unavailable, ineligible, or refused; Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy; Gastric cancer, CRC, esophageal cancer (squamous cell carcinoma or adenocarcinoma), and cholangiocarcinoma: Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; this may include, but does not require, prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor; Other non-CNS solid tumors: Participants must have exhausted, be ineligible for, or refused all standard-of-care therapy appropriate for their disease; Phase 1b:; Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy
• Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
• Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Ki nem vehet részt

• Had previous hemi- or total-body radiation
• Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell [CAR-T therapy, T-cell receptor [TCR] therapy, etc.)
• Have significant cardiovascular disease
• Have prolongation of the corrected QTcF >470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
• Have known active central nervous system (CNS) metastases or carcinomatous meningitis
• Have evidence of ongoing and untreated urinary tract obstruction
• Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI)